Monoclonal antibody specialist Kymab has appointed Arndt Schottelius (pictured above) as its first executive vice president of research and development (R&D).
The UK biotech has numerous therapeutic antibody programs in immuno-oncology, auto-immunity, hematology, infectious disease and other areas, and has raised $220 million of equity financing.
"Kymab can generate a broad diversity of fully human antibodies with great potential to find rare drug candidates with best-in-class characteristics"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze